Announcements Trials
Browse Landscape

Phase

Phase 3 3

Status

Completed 3Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Endocrine 3

Conditions

Pituitary Diseases 3Pituitary ACTH Hypersecretion 3Cushing Syndrome 3ACTH Syndrome, Ectopic 3Hirsutism 2Choristoma 2Adrenal Cortex Neoplasms 2

Interventions

Cyclophosphamide 1499Cisplatin 1435Paclitaxel 1340Radiotherapy 1310Carboplatin 1267Gemcitabine 1226Docetaxel 1133Bevacizumab 1070Fluorouracil 906Doxorubicin 805Dexamethasone 755Rituximab 744Capecitabine 735Oxaliplatin 709pembrolizumab 700Etoposide 679Irinotecan 639Filgrastim 624Cytarabine 587Nivolumab 586Leucovorin 583Vincristine 517Cetuximab 479Prednisone 478Bortezomib 474Trastuzumab 468Erlotinib Hydrochloride 467Surveys and Questionnaires 460Methotrexate 444Lenalidomide 436

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Corlux × Clear all
NCT00936741 2014-04-02

An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome

Corcept Therapeutics

Phase 3 Completed
30 enrolled 8 charts
Endocrine

ACTH Syndrome, Ectopic, Adrenal Cortex Neoplasms, Choristoma, Cushing Syndrome, Hirsutism, Pituitary Diseases, Pituitary ACTH Hypersecretion

NCT01371565 2014-03-18

Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome

Corcept Therapeutics

Phase 3 Completed
4 enrolled 7 charts
Endocrine

ACTH Syndrome, Ectopic, Cushing Syndrome, Pituitary Diseases, Pituitary ACTH Hypersecretion

NCT00569582 2013-08-22

SEISMIC

Corcept Therapeutics

Phase 3 Completed
50 enrolled 8 charts
Endocrine

ACTH Syndrome, Ectopic, Adrenal Cortex Neoplasms, Choristoma, Cushing Syndrome, Hirsutism, Pituitary Diseases, Pituitary ACTH Hypersecretion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡